Issn Print: 1527-6465
Publication Date: 2017/07/01
Vedolizumab is safe and effective in moderate‐to‐severe inflammatory bowel disease following liver transplantation
Andrew P. Wright; Robert J. Fontana; Ryan W. Stidham
Author Information: Division of Gastroenterology Department of Internal Medicine
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.